Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs HubSpot Inc (HUBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs HubSpot Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while HubSpot Inc trades at $209.54 (market cap $10.62B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 3.8× HubSpot Inc's market cap. Which is the better fit depends on your goals.
| ALNY | HUBS | |
|---|---|---|
Market Cap | $39.89B | $10.62B |
Sector | Health | Technology |
52-Week High | $491.22 | $560.90 |
52-Week Low | $278.09 | $170.39 |
Enterprise Value | $38.15B | $9.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
HubSpot (HUBS) trades at $207.48, up 0.74% on the day, showing bullish momentum with strong technical support at $200 and resistance at $213. The company demonstrates robust revenue growth, reaching $3.13 billion in 2025, and has consistently beaten earnings expectations. Analyst sentiment is overwhelmingly positive with an 80.85% buy rating and a consensus price target of $273.53, indicating significant upside potential from current levels.
The outlook for HUBS remains favorable due to accelerating AI integration and customer growth, though high valuation multiples (P/E of 109.2) pose risks if growth slows. Competitive pressures in the CRM space and macroeconomic headwinds could challenge future performance, but strong cash flow generation and expanding margins support a bullish case for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →
